Andrew Baum
Stock Analyst at Citigroup
(2.87)
# 1,587
Out of 5,115 analysts
67
Total ratings
76.74%
Success rate
14.7%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $53 → $60 | $55.05 | +8.99% | 15 | Jan 27, 2026 | |
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $26.44 | -1.66% | 11 | Aug 6, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $115 | $110.27 | +4.29% | 13 | Feb 5, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $41.68 | -4.03% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $223.01 | -3.59% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $1,037.15 | -13.71% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $5.37 | +86.22% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $51.60 | - | 2 | Jul 5, 2017 |
Bristol-Myers Squibb Company
Jan 27, 2026
Maintains: Neutral
Price Target: $53 → $60
Current: $55.05
Upside: +8.99%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $26.44
Upside: -1.66%
Merck & Co.
Feb 5, 2025
Maintains: Buy
Price Target: $125 → $115
Current: $110.27
Upside: +4.29%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $41.68
Upside: -4.03%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $223.01
Upside: -3.59%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $1,037.15
Upside: -13.71%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $5.37
Upside: +86.22%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $51.60
Upside: -